logo-loader
RNS
Physiomics PLC

Physiomics PLC - Operations Update

RNS Number : 8827J
Physiomics PLC
26 June 2026
 
26 June 2026


Physiomics | Physiomics - Model Informed Drug Development - Pharmacometrics, Quantitative System Pharmacology and Biostatistics Consulting

 

Physiomics plc

 

("Physiomics" or the "Company")

 

Operations update

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased is pleased to provide shareholders with an update on the Company's operational progress and strategic development.

 

The Company continues to make strong operational progress as it executes on its strategic priorities and works to strengthen the foundations of the business for future growth. In particular Physiomics is building what is currently its largest commercial pipeline in its history, providing a strong platform for future growth and reinforcing confidence in its market position. The Board of Directors remain encouraged by the level of engagement across both existing and prospective clients and looks forward to updating the market on further contract wins and commercial developments in due course.

 

Inevitably the Company incurred one-off costs ahead of the general meeting in April 2026 in which the former directors were dismissed from their roles.  The current Board has been disappointed with both the level and nature of some of these costs but, more positively, has identified several cost savings, the aggregate effect of which will exceed the exceptional general meeting related expenses, albeit will predominantly be realised in the next financial year.

 

The Board has also welcomed the supportive review of the business prepared by consultant Stewart Williams. The review highlighted a number of areas for development, and the Board believes that the majority of these actions have already been addressed by management.

 

In response to the recommendations arising from the review, the Company has also undertaken a comprehensive assessment of its IT infrastructure and operational systems. This review has confirmed that the business is well positioned to support its growth ambitions and provides a scalable platform capable of onboarding and delivering both existing and larger, more complex client projects. The Board believes these enhancements further strengthen the Company's ability to meet increasing customer demand while maintaining the high standards of service expected by its clients.

 

The Board would also like to acknowledge the continued support of Pete Sargent during this period of transition, Pete has agreed to support the Company where required until the end of August 2026 working at reduced hours as responsibilities are transferred. His contribution remains highly valued, and we look forward to further demonstrating  strong leadership outlook.

 

Outlook

 

The Board believes that significant progress has been made over recent months to strengthen the operational, commercial and financial position of the Company. With an expanding pipeline, improved systems and processes, and a clear strategic direction, Physiomics is well positioned to capitalise on future opportunities.

 

A more comprehensive and in-depth review of the Company's progress, strategy and future opportunities will be provided within the forthcoming annual report. In the meantime, the Board looks forward to updating shareholders on further operational and commercial developments in the weeks ahead, including developments associated with Predict-Onc and DoseMe.

 

Commenting on the Company's financial outlook, Director Ian Bagnall said: "We have identified a robust financial strategy that we believe will support the Company in targeting a path towards breakeven. Whilst the Company has incurred certain one-off costs associated with the previous management structure, the new Board has acted swiftly to implement meaningful operational and financial changes.

 

"Coupled with revenues recognised prior to today's update and anticipated near-term commercial activity, we believe the foundations are being established for a more sustainable and financially resilient business. We remain focused on disciplined execution and maintaining a robust financial strategy as we move forward."

 

ENDS

 

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

 

Enquiries:

Physiomics plc

Mike Whitlow

 

Email:  info@physiomics.co.uk

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

 

Tel:  +44 (0) 20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

Tel:  +44 (0) 20 3764 2341

 

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUNRRRNBUNURR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read